R30

R30 is a monoclonal antibody fragment developed by Shanghai United Cell Biotechnology that targets vascular endothelial growth factor (VEGF). It is designed to bind and neutralize VEGF, thereby inhibiting pathologic angiogenesis and reducing vascular permeability in the retina. The drug is primarily developed for the treatment of various retinal vascular disorders, including wet age-related macular degeneration (AMD), diabetic maculopathy, retinal vascular occlusion, and choroidal neovascularization. As of the latest pipeline updates, a clinical application (interpreted as an NDA/BLA filing) has been submitted for this candidate.

Other names

Shanghai United Cell Biotechnology VEGF monoclonal antibody fragment